# **Next Generation Sequencing**

# XCeloSeq® Breast Cancer cfDNA Kit



# **Highlights**

- Unrivalled Library Complexity powered by ATOM-Seq® capture technology
- · Developed for liquid biopsy samples
- Enhanced Error Correction Error suppression protocol and unique molecular identifiers (UMI)
- Rapid Protocol With High Sample Retention Minimal bead purification and hands on time

Our XCeloSeq® Breast Cancer cfDNA Kit employs our patented ATOM-Seq technology (Adaptor Template Oligo-Mediated Sequencing), which uses a simple and elegant chemistry to capture DNA, using sample DNA molecules as primers themselves, where their 3' ends are extended by a polymerase.


ATOM-Seq adds Unique Molecular Identifiers (UMIs) and universal adapter sequences directly to available 3' ends of every original sample molecule meaning that all original fragments can be captured. A universal primer is then used for rounds of linear amplification, allowing for the sequencing of both sense- and antisense-strands when the linear product is divided between two reactions thereby further improving error correction.

This unique approach is ligation free and is set apart from conventional PCR-based approaches by requiring only a single target-specific primer for enrichment. This offers numerous advantages that make ATOM-Seq particularly well suited to challenging clinical material such as cell-free DNA (cfDNA) from liquid biopsies or FFPE-preserved DNA.


The approach employed by ATOM-Seq along with unique protocol enhancements for sensitivity, specificity, and error correction allows for the highest sample retention and capture efficiency with no compromises on sensitivity and performance.

### **Specifications**





 $<sup>\</sup>ensuremath{^{**}}\textsc{Targeting}$  primers are split between the sense and antisense DNA strands.



#### ATOM-Seg Workflow

Sample DNA is combined with the Adapter Template Oligo. The DNA molecules anneal to the 3' end of the ATO and a polymerase extends the original molecule, using the ATO sequence as a template to add a Unique Molecular Identifier (UMI) and a universal priming site to the end of the captured molecule.





<sup>\*\*\*</sup>Suggested read number for cfDNA samples. Reads should be divided equally between Pool 1 and Pool 2 Libraries. Read numbers can be optimised by users for different uses. For example, for FFPE libraries fewer reads may be sufficient. When using FFPE enzymatic digestion is required.

## **Next Generation Sequencing**



#### Summary

The Breast Cancer cfDNA kit is powered by our ATOM-Seq chemistry and is for use with cell-free DNA extracted from liquid biopsy blood samples. This kit is designed to target selected hotspots across 12 of the most frequently mutated genes in cancers and allows for high sensitivity and specificity detection of mutations including SNPs, insertions, deletions.

When used in conjunction with XCeloSeq Unique Dual Indexing Sets, these allow for the enrichment of nucleic acids to generate high quality, high-complexity next-generation sequencing libraries suitable for use with Illumina\* next-generation sequencing (NGS) instruments.

### Ordering Information


Product	No. of Samples	Catalog No.
XCeloSeq® Breast Cancer cfDNA	8	SEQ011

#### Learn more

For more information including the protocol please visit www.genefirst.com

### Further Information

Dunwell TL, Dailey SC, et al. Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNA. Sci Rep. 2021 Feb 4;11(1):3138. doi: 10.1038/s41598-021-82737-9. PMID: 33542447; PMCID: PMC7862664.



Final NGS Library

Total Time: <5.5 hours Hands-on Time: <2.0 hours

XCeloSeq® Breast Cancer cfDNA Workflow.

AKT	EGFR	ERBB3	ESR1	FBXW7	FGFR1	KRAS	PIK2CA	SF3B1	TP53*
CCND1	ERBB2								

XCeloSeg® Breast Cancer cfDNA Kit Assay Targets. Selected target regions are enriched for the above genes (\*Whole Coding Region Coverage).

© 2023 GeneFirst limited or one of its subsidiaries. ATOM-Seq and XCeloSeq are trademarks of GeneFirst Limited or one of its subsidiaries. All rights reserved. GeneFirst Limited pursues a policy of continuing improvement in design, production, and performance of its products. The right is therefore reserved to vary at any time and without notice.

Doc No: LIT1118v4.0

GeneFirst Limited • +44(0) 1865 407400 • www.genefirst.com

For Research Use Only. Not for use in diagnostic procedures



QR code to Website